A o r t i c V A lV e D i s e A s e i s c o m m o n i n e l D e r ly P A t i e n t s
As the chart illustrates, aortic valve disease is common and its prevalence increases with age. For people over the age of 75 years, the prevalence of aortic stenosis is 5%. 4 More than one in eight people over the age of 75 have moderate or severe valve disease. 1 As the population ages, this condition becomes an important public health problem.
new options for Aortic Valve replacement
Epidemiological studies have determined that more than one in eight people aged 75 and older have moderate or severe aortic stenosis (AS). 1 Multiple surveys have
shown that many patients with severe AS are not referred to a heart team for valve replacement evaluation. 2 Surgical aortic valve replacement (SAVR) is the gold standard for treatment of severe AS and transcatheter aortic valve implantation (TAVI) offers a new treatment option for patients considered high risk for surgery.
Here is how you can help.
"Valvular heart diseases represent an under appreciated yet serious and growing public health problem that should be addressed." 
A o r t i c s t e n o s i s i s l i f e -t h r e A t e n i n g
Valvular aortic stenosis is progressive and life-threatening. Once symptoms appear, untreated patients have a poor prognosis; they will experience worsening symptoms, eventually leading to death. After the onset of symptoms, average survival is 50% at two years and 20% at five years. Progression of Aortic Stenosis 
A o r t i c s t e n o s i s t r e A t m e n t g u i D e l i n e s
According to the ESC Guidelines, severe AS is defined by these characteristics:
The 2012 ESC/EACTS guidelines for AS recommend valve replacement for Class I patients, i.e. those with severe AS and symptoms 8 . TAVI is indicated in patients with severe symptomatic AS who are not suitable for AVR as assessed by a "heart team" and should be considered in high risk patients who may still be suitable for surgery, but in whom TAVI is favoured by a "heart team" based on the individual risk profile. 
ESC/EACTS AS Treatment Guidelines 8 t r e A t m e n t i s u r g e n t A n D A o r t i c V A lV e r e P l A c e m e n t i s e f f e c t i V e
There are no medications to reverse or slow the progression of AS. AVR is the standard of care. Because of the risk of sudden death, AVR should be performed promptly after the onset of symptoms. 9 Without timely aortic valve replacement, patients with severe AS and symptoms have high mortality: mortality is 3% to 4% soon after symptoms appear and 7% among patients on a waiting list for AVR. In contrast, mortality in a fit patient is 1% to 2% after AVR. 5 In recent decades, surgical AVR has consistently produced outstanding results in prolonging life and improving quality of life. 8, 11, 12, 13 Even among patients over the age of 80 years, functional outcomes have been excellent in patients after AVR. 13 Survival is good, with 60% to 65% of patients who underwent AVR alive five years later, 11, 12 with improved quality of life. 8 
t i c s t e n o s i s P A t i e n t s A r e n o t t r e A t e D

r e A s o n s m A n y A o r t i c s t e n o s i s P A t i e n t s D o n ' t g e t n e e D e D t r e A t m e n t
Treatment decisions for older patients with severe AS are challenging due to comorbidity; they have a higher operative risk and have reduced life expectancy. In addition, their risk is increased by comorbidities such as heart disease and other conditions that are often present in this age group. 
r A n s c A t h e t e r t r e A t m e n t o P t i o n A D D r e s s e s A n u n m e t n e e D
A new option for patients with severe AS considered to be high risk for surgical 
Transapical
Valve Implantation
Transaortic
Valve Implantation t h e P A r t n e r t r i A l
The PARTNER (Placement of AoRtic TraNscathetER Valves) trial represents a paradigm shift in clinical investigation and interpretability. As the world's first prospective, randomized, and controlled trial for transcatheter heart valves, the PARTNER trial sets new standards in site selection, case screening, study management, multidisciplinary teamwork, and patient follow-up. 22 The PARTNER Trial consists of two individually powered patient cohorts.
• In Cohort A, the safety and effectiveness of the Edwards SAPIEN transcatheter heart valve (THV) was compared to surgical aortic valve replacement (sAVR) in high-risk patients with severe aortic stenosis. The results of Cohort A were published in 2011. 22 • In Cohort B, the safety and effectiveness of the Edwards SAPIEN THV was compared to best medical management (standard therapy) in inoperable patients with severe aortic stenosis. Patient selection required at least two cardiothoracic surgeons and an interventional cardiologist to agree that patients were not suitable candidates for surgery. 
Porcelain aorta 15%
Chest wall deformity 7%
CAD 71%
Frail 23% 
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An increasing number of heart centers offer all of the available AS solutions. Referral to such a center offers the most options for your patients. A multidisciplinary approach is necessary in order to direct each patient toward the best therapeutic option. The team will evaluate patients for surgical AVR, balloon valvuloplasty, TAVI, or medical management.
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